The fight against Alzheimer’s disease—a disease that robs individuals of their memories and independence—has reached a pivotal juncture. New research suggests that Gantenerumab, an investigational antibody treatment, may not only slow down the devastating progression of this condition in diagnosed patients but also prevent its debilitating onset in those genetically predisposed to Alzheimer’s. The research,
0 Comments
In an era defined by escalating geopolitical tensions, the European Union (EU) is presently on the verge of a significant shift in its defense strategy—a shift worth approximately 800 billion euros ($867 billion). This monumental proposal, introduced by the European Commission, has sparked a mixture of enthusiasm and skepticism among member states. Some leaders are
0 Comments
Fremantle’s recent financial results echo a tale of paradoxes where a remarkable 23% profit increase contrasts sharply with a stalling turnover target. The super-indie’s adjusted EBITA reached €171 million for the fiscal year 2024, an impressive milestone that marks the highest profit level achieved to date. Delfin to RTL, the company’s parent organization, ascribes this
0 Comments